GSK PLC

GSK will report Q3 results, projecting £8 billion in revenue, down from £8.15 billion last year, with net profit rising to £1.78 billion. A £1.8 billion charge for Zantac won't affect 2024 guidance.

GSK covers 80% of IDE275's global R&D costs. With the FDA approving IDEAYA Biosciences' new drug application for IDE275, GSK will receive a $7 million milestone payment.

GSK is identified as a major player in the RSV market, alongside Moderna and Pfizer, and is experiencing impacts from lower vaccination rates for RSV compared to the previous year.